Tenofovir disoproxil fumarate for the treatment of HIV infection

Paul A. Pham, Joel E. Gallant

Research output: Contribution to journalArticle

Abstract

Tenofovir disoproxil fumarate is a nucleotide analogue reverse transcriptase inhibitor approved by the FDA for the treatment of HIV infection. It is a potent agent with a long intracellular half-life that allows for once-daily dosing. It has been well tolerated in clinical trials, without evidence of the mitochondrial toxicity that has been associated with long-term treatment of some of the nucleoside analogue reverse transcriptase inhibitors. Because of its demonstrated efficacy and favourable safety profile, tenofovir disoproxil fumarate has quickly become a favoured nucleoside component of antiretroviral regimens for both treatment-naive and -experienced patients.

Original languageEnglish (US)
Pages (from-to)459-469
Number of pages11
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume2
Issue number3
DOIs
StatePublished - Dec 1 2006

Keywords

  • AIDS
  • Antiretroviral therapy
  • HIV infection
  • Nucleotide analogue reverse transcriptase inhibitor
  • Tenofovir

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology

Fingerprint Dive into the research topics of 'Tenofovir disoproxil fumarate for the treatment of HIV infection'. Together they form a unique fingerprint.

  • Cite this